Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
21 10 2020
Historique:
received: 08 10 2020
revised: 16 10 2020
accepted: 19 10 2020
entrez: 24 10 2020
pubmed: 25 10 2020
medline: 23 2 2021
Statut: epublish

Résumé

H-1 protoparvovirus (H-1PV) is a self-propagating virus that is non-pathogenic in humans and has oncolytic and oncosuppressive activities. H-1PV is the first member of the

Identifiants

pubmed: 33096814
pii: v12101199
doi: 10.3390/v12101199
pmc: PMC7594094
pii:
doi:

Substances chimiques

Clathrin 0
Dynamins EC 3.6.5.5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Arch Virol. 2014 May;159(5):1239-47
pubmed: 24212889
J Virol. 2010 Jun;84(12):5909-22
pubmed: 20375165
Traffic. 2005 Dec;6(12):1070-7
pubmed: 16262719
Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17148-53
pubmed: 16284249
Retrovirology. 2012 Oct 15;9:85
pubmed: 23067370
EMBO Mol Med. 2013 Oct;5(10):1537-55
pubmed: 24092664
Cell. 2011 Aug 5;146(3):471-84
pubmed: 21816279
J Vis Exp. 2012 Apr 23;(62):
pubmed: 22546707
Virology. 2012 Oct 10;432(1):110-9
pubmed: 22748181
Dev Cell. 2001 Aug;1(2):291-302
pubmed: 11702787
Mol Biol Cell. 1999 Apr;10(4):961-74
pubmed: 10198050
J Virol. 2012 Sep;86(17):9274-84
pubmed: 22718826
J Virol. 2009 May;83(9):4678-89
pubmed: 19225003
J Virol. 2003 Oct;77(19):10270-9
pubmed: 12970411
Mol Biol Cell. 1996 Nov;7(11):1825-34
pubmed: 8930903
J Biol Chem. 1991 Sep 15;266(26):17707-12
pubmed: 1832676
Nat Rev Mol Cell Biol. 2011 Jul 22;12(8):517-33
pubmed: 21779028
J Virol. 2008 Feb;82(3):1128-35
pubmed: 18032516
Cell Commun Signal. 2015 Apr 10;13:24
pubmed: 25889964
J Virol Methods. 2016 Mar;229:48-59
pubmed: 26658622
J Virol. 2000 Feb;74(4):1919-30
pubmed: 10644365
Annu Rev Biochem. 2010;79:803-33
pubmed: 20196649
J Cell Biol. 1993 Dec;123(5):1107-17
pubmed: 8245121
Annu Rev Biochem. 2009;78:857-902
pubmed: 19317650
J Virol. 2004 Jun;78(11):5601-11
pubmed: 15140957
PLoS Biol. 2013;11(8):e1001639
pubmed: 24013596
Mol Pharmacol. 2017 Feb;91(2):123-134
pubmed: 27879341
BMC Cancer. 2017 Aug 29;17(1):576
pubmed: 28851316
Clin Cancer Res. 2012 Jul 1;18(13):3516-23
pubmed: 22566376
Mol Aspects Med. 2006 Oct-Dec;27(5-6):495-502
pubmed: 16973206
J Cell Biol. 2018 Jun 4;217(6):1883
pubmed: 32005038
Viruses. 2019 Jun 18;11(6):
pubmed: 31216641
J Gen Virol. 2010 Dec;91(Pt 12):3032-41
pubmed: 20810750
Trends Microbiol. 2008 May;16(5):208-14
pubmed: 18406140
J Virol. 2018 Jul 17;92(15):
pubmed: 29769350
J Cell Biol. 1989 Feb;108(2):389-400
pubmed: 2563728
J Biol Chem. 2004 Apr 9;279(15):14502-8
pubmed: 14726513
Cancer Gene Ther. 2011 Apr;18(4):240-9
pubmed: 21102423
J Virol. 2007 Apr;81(8):4186-98
pubmed: 17287256
Trends Cell Biol. 2003 Mar;13(3):137-45
pubmed: 12628346
J Virol. 2006 Jan;80(2):1015-24
pubmed: 16379002
Front Immunol. 2019 Aug 07;10:1848
pubmed: 31440242
J Med Chem. 2009 Jun 25;52(12):3762-73
pubmed: 19459681
Virology. 2015 Aug;482:157-66
pubmed: 25863880
J Virol. 2002 Dec;76(24):12634-45
pubmed: 12438589
Annu Rev Virol. 2020 Sep 29;7(1):537-557
pubmed: 32600158
Virology. 2014 Aug;462-463:241-53
pubmed: 24999049
Biochim Biophys Acta. 2012 Mar;1820(3):264-81
pubmed: 21968002
BMC Cancer. 2012 Mar 21;12:99
pubmed: 22436661
J Biol Chem. 1995 Jul 21;270(29):17250-6
pubmed: 7615524
Trends Cell Biol. 1995 Nov;5(11):424-8
pubmed: 14732047
Mol Biol Cell. 2000 Aug;11(8):2657-71
pubmed: 10930461
Viruses. 2017 Oct 26;9(11):
pubmed: 29072600
J Virol. 2010 Aug;84(15):7782-92
pubmed: 20484503
Nat Protoc. 2014 Apr;9(4):851-70
pubmed: 24651498
J Cell Biol. 2017 Jan 2;216(1):167-179
pubmed: 28003333
J Virol. 2012 Apr;86(7):3452-65
pubmed: 22258256
J Virol. 2002 Feb;76(4):1884-91
pubmed: 11799183
Adv Virus Res. 2007;70:183-232
pubmed: 17765706
Virology. 1992 Feb;186(2):368-76
pubmed: 1733094
J Virol. 2002 May;76(9):4401-11
pubmed: 11932407
J Virol. 1998 Jan;72(1):802-6
pubmed: 9420290
J Virol. 2006 Feb;80(3):1563-73
pubmed: 16415031

Auteurs

Tiago Ferreira (T)

Laboratory of Oncolytic Virus Immuno-Therapeutics, German Cancer Research Centre, Im Neuenheimer Feld 242, 69120 Heidelberg, Germany.

Amit Kulkarni (A)

Laboratory of Oncolytic Virus Immuno-Therapeutics, Luxembourg Institute of Health, 84 Val Fleuri, L-1526 Luxembourg, Luxembourg.

Clemens Bretscher (C)

Laboratory of Oncolytic Virus Immuno-Therapeutics, German Cancer Research Centre, Im Neuenheimer Feld 242, 69120 Heidelberg, Germany.

Karsten Richter (K)

Core Facility Electron Microscopy, German Cancer Research Centre, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.

Marcelo Ehrlich (M)

Laboratory of Signal Transduction and Membrane Biology, The Shumins School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Lux69978 Tel Aviv, Israel.

Antonio Marchini (A)

Laboratory of Oncolytic Virus Immuno-Therapeutics, German Cancer Research Centre, Im Neuenheimer Feld 242, 69120 Heidelberg, Germany.
Laboratory of Oncolytic Virus Immuno-Therapeutics, Luxembourg Institute of Health, 84 Val Fleuri, L-1526 Luxembourg, Luxembourg.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH